ALZHEON
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated with neurodegeneration. They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders.
ALZHEON
Industry:
Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2013-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.alzheon.com
Total Employee:
11+
Status:
Active
Contact:
+1 857 214-7242
Email Addresses:
[email protected]
Total Funding:
136.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Current Advisors List
Current Employees Featured
Founder
Investors List
National Institute on Aging
National Institute on Aging investment in Grant - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series B - Alzheon
Scott H. Cohen
Scott H. Cohen investment in Series A - Alzheon
Ally Bridge Group
Ally Bridge Group investment in Series A - Alzheon
Key Employee Changes
Official Site Inspections
http://www.alzheon.com Semrush global rank: 2.92 M Semrush visits lastest month: 5.58 K
- Host name: 61.171.211.130.bc.googleusercontent.com
- IP address: 130.211.171.61
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Alzheon" on Search Engine
Alzheon - Wikipedia
Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, a veteran of Alzheimer's drug programs, who serves as president and CEO of the organization. Alzheon completed a $10 million Series A round of financing in April 2015 and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016. In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairma…See details»
About | Medicines for Alzheimer's Disease - Alzheon
Alzheon is a clinical-stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of …See details»
Alzheon, Inc. | Preserving Future Memories | LinkedIn
Alzheon, Inc. | Preserving Future Memories | 4,076 followers on LinkedIn. Developing treatments to slow or stop Alzheimer’s disease & other devastating neurological …See details»
Alzheon Announces that United States Federal Circuit Affirmed …
FRAMINGHAM, Mass., April 08, 2024--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for …See details»
Alzheon Announces First Patient Dosed in APOLLOE4 …
Jun 4, 2021 FRAMINGHAM, Mass.-- ( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering …See details»
Alzheon Announces Early Completion of Enrollment of …
Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024 Safety Profile in ALZ-801 Studies Remains Favorable …See details»
Alzheon to Present Biomarker, Brain Preservation, and Clinical …
FRAMINGHAM, Mass., February 27, 2024 -- ( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and …See details»
Alzheon Initiates Open-Label Extensions for Phase 2 and 3 …
May 1, 2024 Alzheon, the drug manufacturers of ALZ-801, an investigational oral disease-modifying therapy in development for early-stage Alzheimer disease (AD), has …See details»
Alzheon CEO Dr. Martin Tolar to Present ALZ …
FRAMINGHAM, Mass., January 03, 2024 -- ( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates …See details»
Alzheimer’s Drug Developer Alzheon Secures $50 Million
Biotech company is testing oral medication in Phase 3 clinical trialsBiotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a …See details»
Alzheimer’s Drug Developer Alzheon Secures $50 Million
By Brian Gormley. April 14, 2022 7:30 am ET | WSJ Pro. Share. Resize. Alzheon Inc. Chief Executive Martin Tolar Photo: Alzheon. Biotechnology company Alzheon Inc. has raised …See details»
Alzheon - Crunchbase Company Profile & Funding
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative. Lexington, Massachusetts, United States. 11 …See details»
Alzheon to Present Biomarker, Brain Preservation, and Clinical …
FRAMINGHAM, Mass., October 17, 2023 -- ( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and …See details»
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 …
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease - Alzheon | Preserving Future Memories.See details»
Alzheon to Present Biomarker, Brain Preservation, and
Feb 27, 2024 Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on …See details»
APOE4 homozygozity represents a distinct genetic form of
May 6, 2024 The study on APOE4 homozygosity indicates a genetic variant of Alzheimer’s disease with early symptom onset and distinct biomarker progression, highlighting the …See details»
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer …
Dec 5, 2023 Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from …See details»
In The News - Alzheon | Preserving Future Memories
Discover the latest news and updates about Alzheon, a biopharmaceutical company dedicated to preserving future memories for Alzheimer's patients.See details»
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer …
FRAMINGHAM, Mass., December 05, 2023 -- ( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product …See details»
Alzheon - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Alzheon. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 10. Number of Board Member …See details»